Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)

NCT07408089 is registered in ClinicalTrials.gov with Boundless Bio, Inc. as lead sponsor.

NCT NCT07408089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07408089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)
Lead sponsor
Boundless Bio, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 25, 2026
Completion date
July 28, 2026
Enrollment
8 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, metastatic breast cancer